- Home
- » Tags
- » Generic drug
Top View
- ANDA 207740 ANDA APPROVAL Dr. Reddy's Laboratories Inc. U.S
- FDA Approval Letter
- In the United States District Court for the Middle District of Pennsylvania Harrisburg Division
- Your 2016 Formulary
- Biosimilar Vs. Generic, What's the Difference?
- The Emergence of India's Pharmaceutical Industry
- Dr Reddy's Launches Generic Version of Triglyceride Lowering Drug Vascepa in US
- Tiered Generic Prescription Drug Guide, October 2019 I
- FDA Approval Letter
- Generic Drugs
- Thyroid Hormone Use in the United States, 1997–2016
- Exclusivity and Generic Drugs: What Does It Mean?
- Prescription Drug Resource Center Generic Drug Substitution Laws May 3, 2019 Compiled by the NCSL Health Program
- Fda Has Made Progress on Oversight and Inspections of Manufacturers of Generic Drugs Oei-01-13-00600
- Androgel Second Amended Complaint for Injunctive and Other
- Get to Know Biosimilars a Primer What Are Biosimilars?
- The First Thing You Should Know About Biosimilar Inds to the US FDA
- United States Court of Appeals for the Seventh Circuit ______No
- Prescription Drug Program Formulary Updates
- FOI Summary for the Original Approval of ANADA 200-635 October 29, 2019
- Massachusetts Commercial Formulary Prescription Drug List by Tier
- Merck & Co., Inc
- A Briefing Book Rx Drug Debate
- Battle for the Market: Branded Drug Companies' Secret Weapons
- Generic Drugs: the Same Medicine for Less Money
- Top 10 Facts on Generic Drugs
- 2019 Prescription Drug List Traditional Three-Tier
- Complaint for Injunctive and Other Equitable Relief [Redacted Public Version]
- PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Generic Additions These Generic Drugs Recently Became Available in the Marketplace
- Dr. Reddy's Laboratories Announces the Launch of Pyrimethamine Tablets USP, 25 Mg, First-Wave Generic Version of Daraprim® in the U.S
- Sanofi-Aventis/Zentiva Case No COMP/M5253
- 1.0 Dr. Reddy's Laboratories Limited
- Generic Drug Competition: the Pharmaceutical Industry “Gaming” Controversy
- Merck & Co., Inc
- United States District Court for the District of Columbia ______) Sanofi-Aventis U.S
- Generic and Brand Name Drugs: Understanding the Basics
- The Clinical Utility of Compounded Bioidentical Hormone Therapy: a Review of Safety, Effectiveness, and Use (2020)
- CVS Caremark® Value Formulary Effective As of 07/01/2021
- Harris Cty.Generics Complaint.3.1.FINAL
- Generic Atorvastatin Is As Effective As the Brand-Name Drug (LIPITOR®)
- March 9, 2017 Legislative Update Meeting Supplemental Material Regarding SB233
- 160915Teva-Allergan-Cmpt.Pdf
- Generic Pharmaceutical Manufacturing in the US May 2019 1
- Androgel® (Testosterone Gel) 1.62%
- The Case for Competition 2019 Generic Drug & Biosimilars Access & Savings in the U.S
- Introduction to the Generic Drug Supply Chain and Key Considerations for Policymakers
- Mylan Agrees to Pay $465 Million to Resolve False Claims Act Liability
- Form 20-F 2020 | 1 Part I Item 3
- The Impact of Changing Branded Statins Into Generic Drugs at the National Guard Hospital in Riyadh, Saudi Arabia Abdulaziz Dahham N
- Generic-Drug Manufacturer's Supply Chain Ills
- Annual Report on Form 20-F 2018
- MHDL Update Change in Prior-Authorization
- Generic Drugs: Myths and Facts
- CVS Caremark® Value Priced Generic Drug List
- Generic Pharmaceutical Industry Yearbook
- Biosimilars Vs. Generics. Biosimilars Are Becoming More and More Common in the United States
- Study Synopsis
- Top 10 Facts on Generic Drugs
- Why Prices Can Remain High for Off-Patent Drugs, 71 HASTINGS L.J
- Christopher Speakes, Et Al. V. Taro Pharmaceutical Industries, Ltd., Et Al. 16-CV-08318-Corrected Amended Class Action Complain
- What Drugs Do Medicare Drug Plans Cover?
- GAO-16-706, Generic Drugs Under Medicare
- Facts About Generic Drugs
- Pharmacy Policy Changes for Adderall XR Effective May 1, 2019
- ACA Preventive Drug List Effective January 1, 2021
- Generic Drug Science and Research Initiatives Public Workshop Final
- Gaining Market Share in the Generic Drug Industry Through Acquisitions and Partnerships
- Testosterone Gel 1.62% CIII FDA Approval Letter